The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial

Spirometry Outcomes

Antonio Anzueto, Robert A Wise, Peter Calverley, Daniel Dusser, Wenbo Tang, Norbert Metzdorf, Ronald Dahl

Research output: Contribution to journalArticle

Abstract

Background: Tiotropium Safety and Performance in Respimat® (TIOSPIR®) compared the safety and efficacy of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease (COPD). A prespecified spirometry substudy compared the lung function efficacy between treatment groups. Methods: TIOSPIR® was a large-scale, long-term (2.3-year), event-driven, randomized, double-blind, parallel-group trial of 17,135 patients with COPD. In the spirometry substudy, trough forced expiratory volume in 1second (FEV1) and forced vital capacity (FVC) were measured at baseline and every 24weeks for the duration of the trial. Results: The substudy included 1370 patients who received once-daily tiotropium Respimat® 5 μg (n = 461), 2.5 μg (n = 464), or tiotropium HandiHaler® 18 μg (n = 445). Adjusted mean trough FEV1 (average 24-120 weeks) was 1.285, 1.258, and 1.295L in the Respimat® 5 μg, 2.5 μg, and HandiHaler® 18 μg groups (difference versus HandiHaler® [95% CI]: -10 [-38, 18] mL for Respimat® 5 μg and, -37 [-65, -9] mL for Respimat® 2.5 μg); achieving noninferiority to tiotropium HandiHaler® 18 μg for tiotropium Respimat® 5 but not for 2.5 μg (prespecified analysis). Adjusted mean trough FVC was 2.590, 2.544, and 2.593L in the Respimat® 5 μg, 2.5 μg, and HandiHaler® 18 μg groups. The rates of FEV1 decline over 24 to 120weeks were similar for the three treatment arms (26, 40, and 34mL/year for the tiotropium Respimat® 5- μg, 2.5- μg, and HandiHaler® 18- μg groups). The rate of FEV1 decline in GOLD I + II patients was greater than in GOLD III + IV patients (46 vs. 23mL/year); as well as in current versus ex-smokers, in patients receiving combination therapies at baseline versus not, and in those experiencing an exacerbation during the study versus not. Conclusions: The TIOSPIR® spirometry substudy showed that tiotropium Respimat® 5 μg was noninferior to tiotropium HandiHaler® 18 μg for trough FEV1, but Respimat® 2.5 μg was not. Tiotropium Respimat® 5 μg provides similar bronchodilator efficacy to tiotropium HandiHaler® 18 μg with comparable rates of FEV1 decline. The rate of FEV1 decline varied based on disease severity, with a steeper rate of decline observed in patients with moderate airway obstruction. Trial registration:NCT01126437 .

Original languageEnglish (US)
Article number107
JournalRespiratory Research
Volume16
Issue number1
DOIs
StatePublished - Sep 15 2015

Fingerprint

Spirometry
Safety
Forced Expiratory Volume
Vital Capacity
Tiotropium Bromide
Chronic Obstructive Pulmonary Disease
Bronchodilator Agents
Airway Obstruction

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial : Spirometry Outcomes. / Anzueto, Antonio; Wise, Robert A; Calverley, Peter; Dusser, Daniel; Tang, Wenbo; Metzdorf, Norbert; Dahl, Ronald.

In: Respiratory Research, Vol. 16, No. 1, 107, 15.09.2015.

Research output: Contribution to journalArticle

Anzueto, Antonio ; Wise, Robert A ; Calverley, Peter ; Dusser, Daniel ; Tang, Wenbo ; Metzdorf, Norbert ; Dahl, Ronald. / The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial : Spirometry Outcomes. In: Respiratory Research. 2015 ; Vol. 16, No. 1.
@article{62939b2a500e4feab6a662106331d1bf,
title = "The Tiotropium Safety and Performance in Respimat{\circledR} (TIOSPIR{\circledR}) Trial: Spirometry Outcomes",
abstract = "Background: Tiotropium Safety and Performance in Respimat{\circledR} (TIOSPIR{\circledR}) compared the safety and efficacy of tiotropium Respimat{\circledR} and tiotropium HandiHaler{\circledR} in patients with chronic obstructive pulmonary disease (COPD). A prespecified spirometry substudy compared the lung function efficacy between treatment groups. Methods: TIOSPIR{\circledR} was a large-scale, long-term (2.3-year), event-driven, randomized, double-blind, parallel-group trial of 17,135 patients with COPD. In the spirometry substudy, trough forced expiratory volume in 1second (FEV1) and forced vital capacity (FVC) were measured at baseline and every 24weeks for the duration of the trial. Results: The substudy included 1370 patients who received once-daily tiotropium Respimat{\circledR} 5 μg (n = 461), 2.5 μg (n = 464), or tiotropium HandiHaler{\circledR} 18 μg (n = 445). Adjusted mean trough FEV1 (average 24-120 weeks) was 1.285, 1.258, and 1.295L in the Respimat{\circledR} 5 μg, 2.5 μg, and HandiHaler{\circledR} 18 μg groups (difference versus HandiHaler{\circledR} [95{\%} CI]: -10 [-38, 18] mL for Respimat{\circledR} 5 μg and, -37 [-65, -9] mL for Respimat{\circledR} 2.5 μg); achieving noninferiority to tiotropium HandiHaler{\circledR} 18 μg for tiotropium Respimat{\circledR} 5 but not for 2.5 μg (prespecified analysis). Adjusted mean trough FVC was 2.590, 2.544, and 2.593L in the Respimat{\circledR} 5 μg, 2.5 μg, and HandiHaler{\circledR} 18 μg groups. The rates of FEV1 decline over 24 to 120weeks were similar for the three treatment arms (26, 40, and 34mL/year for the tiotropium Respimat{\circledR} 5- μg, 2.5- μg, and HandiHaler{\circledR} 18- μg groups). The rate of FEV1 decline in GOLD I + II patients was greater than in GOLD III + IV patients (46 vs. 23mL/year); as well as in current versus ex-smokers, in patients receiving combination therapies at baseline versus not, and in those experiencing an exacerbation during the study versus not. Conclusions: The TIOSPIR{\circledR} spirometry substudy showed that tiotropium Respimat{\circledR} 5 μg was noninferior to tiotropium HandiHaler{\circledR} 18 μg for trough FEV1, but Respimat{\circledR} 2.5 μg was not. Tiotropium Respimat{\circledR} 5 μg provides similar bronchodilator efficacy to tiotropium HandiHaler{\circledR} 18 μg with comparable rates of FEV1 decline. The rate of FEV1 decline varied based on disease severity, with a steeper rate of decline observed in patients with moderate airway obstruction. Trial registration:NCT01126437 .",
author = "Antonio Anzueto and Wise, {Robert A} and Peter Calverley and Daniel Dusser and Wenbo Tang and Norbert Metzdorf and Ronald Dahl",
year = "2015",
month = "9",
day = "15",
doi = "10.1186/s12931-015-0269-4",
language = "English (US)",
volume = "16",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial

T2 - Spirometry Outcomes

AU - Anzueto, Antonio

AU - Wise, Robert A

AU - Calverley, Peter

AU - Dusser, Daniel

AU - Tang, Wenbo

AU - Metzdorf, Norbert

AU - Dahl, Ronald

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Background: Tiotropium Safety and Performance in Respimat® (TIOSPIR®) compared the safety and efficacy of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease (COPD). A prespecified spirometry substudy compared the lung function efficacy between treatment groups. Methods: TIOSPIR® was a large-scale, long-term (2.3-year), event-driven, randomized, double-blind, parallel-group trial of 17,135 patients with COPD. In the spirometry substudy, trough forced expiratory volume in 1second (FEV1) and forced vital capacity (FVC) were measured at baseline and every 24weeks for the duration of the trial. Results: The substudy included 1370 patients who received once-daily tiotropium Respimat® 5 μg (n = 461), 2.5 μg (n = 464), or tiotropium HandiHaler® 18 μg (n = 445). Adjusted mean trough FEV1 (average 24-120 weeks) was 1.285, 1.258, and 1.295L in the Respimat® 5 μg, 2.5 μg, and HandiHaler® 18 μg groups (difference versus HandiHaler® [95% CI]: -10 [-38, 18] mL for Respimat® 5 μg and, -37 [-65, -9] mL for Respimat® 2.5 μg); achieving noninferiority to tiotropium HandiHaler® 18 μg for tiotropium Respimat® 5 but not for 2.5 μg (prespecified analysis). Adjusted mean trough FVC was 2.590, 2.544, and 2.593L in the Respimat® 5 μg, 2.5 μg, and HandiHaler® 18 μg groups. The rates of FEV1 decline over 24 to 120weeks were similar for the three treatment arms (26, 40, and 34mL/year for the tiotropium Respimat® 5- μg, 2.5- μg, and HandiHaler® 18- μg groups). The rate of FEV1 decline in GOLD I + II patients was greater than in GOLD III + IV patients (46 vs. 23mL/year); as well as in current versus ex-smokers, in patients receiving combination therapies at baseline versus not, and in those experiencing an exacerbation during the study versus not. Conclusions: The TIOSPIR® spirometry substudy showed that tiotropium Respimat® 5 μg was noninferior to tiotropium HandiHaler® 18 μg for trough FEV1, but Respimat® 2.5 μg was not. Tiotropium Respimat® 5 μg provides similar bronchodilator efficacy to tiotropium HandiHaler® 18 μg with comparable rates of FEV1 decline. The rate of FEV1 decline varied based on disease severity, with a steeper rate of decline observed in patients with moderate airway obstruction. Trial registration:NCT01126437 .

AB - Background: Tiotropium Safety and Performance in Respimat® (TIOSPIR®) compared the safety and efficacy of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease (COPD). A prespecified spirometry substudy compared the lung function efficacy between treatment groups. Methods: TIOSPIR® was a large-scale, long-term (2.3-year), event-driven, randomized, double-blind, parallel-group trial of 17,135 patients with COPD. In the spirometry substudy, trough forced expiratory volume in 1second (FEV1) and forced vital capacity (FVC) were measured at baseline and every 24weeks for the duration of the trial. Results: The substudy included 1370 patients who received once-daily tiotropium Respimat® 5 μg (n = 461), 2.5 μg (n = 464), or tiotropium HandiHaler® 18 μg (n = 445). Adjusted mean trough FEV1 (average 24-120 weeks) was 1.285, 1.258, and 1.295L in the Respimat® 5 μg, 2.5 μg, and HandiHaler® 18 μg groups (difference versus HandiHaler® [95% CI]: -10 [-38, 18] mL for Respimat® 5 μg and, -37 [-65, -9] mL for Respimat® 2.5 μg); achieving noninferiority to tiotropium HandiHaler® 18 μg for tiotropium Respimat® 5 but not for 2.5 μg (prespecified analysis). Adjusted mean trough FVC was 2.590, 2.544, and 2.593L in the Respimat® 5 μg, 2.5 μg, and HandiHaler® 18 μg groups. The rates of FEV1 decline over 24 to 120weeks were similar for the three treatment arms (26, 40, and 34mL/year for the tiotropium Respimat® 5- μg, 2.5- μg, and HandiHaler® 18- μg groups). The rate of FEV1 decline in GOLD I + II patients was greater than in GOLD III + IV patients (46 vs. 23mL/year); as well as in current versus ex-smokers, in patients receiving combination therapies at baseline versus not, and in those experiencing an exacerbation during the study versus not. Conclusions: The TIOSPIR® spirometry substudy showed that tiotropium Respimat® 5 μg was noninferior to tiotropium HandiHaler® 18 μg for trough FEV1, but Respimat® 2.5 μg was not. Tiotropium Respimat® 5 μg provides similar bronchodilator efficacy to tiotropium HandiHaler® 18 μg with comparable rates of FEV1 decline. The rate of FEV1 decline varied based on disease severity, with a steeper rate of decline observed in patients with moderate airway obstruction. Trial registration:NCT01126437 .

UR - http://www.scopus.com/inward/record.url?scp=84941565154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941565154&partnerID=8YFLogxK

U2 - 10.1186/s12931-015-0269-4

DO - 10.1186/s12931-015-0269-4

M3 - Article

VL - 16

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

IS - 1

M1 - 107

ER -